Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic polymorphism of urokinase-type plasminogen activator is interacting with plasminogen activator inhibitor-1 to raise risk of cervical neoplasia.

Journal of surgical oncology - 1 Aug 2012

Tee Yi-Torng, Wang Po-Hui, Tsai Hsiu-Ting, Lin Long-Yau, Lin Hung-Ting, Yang Shun-Fa, Hsieh Yi-Hsien, Ying Tsung-Ho

Abstract excerpt

BACKGROUND AND OBJECTIVES: To evaluate the impact of plasminogen activator (PA) system genes, including urokinase plasminogen activator (uPA), uPA receptor (uPAR), and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms in patients with the cervical neoplasia. METHODS: In total, 336 blood samples were collected from healthy women and 136 patients with cervical neoplasia to analyze the gene polymorphisms...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Odds Ratio
Share to Plasminogen Activator Inhibitor 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polymerase Chain Reaction

Share to Polymorphism, Restriction Fragment Length

Share to Risk Assessment

Share to Risk Factors

Share to Urokinase-Type Plasminogen Activator

Share to Uterine Cervical Neoplasms

Source

Identifiers

PMID: 22354580
DOI: 10.1002/jso.23072

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic polymorphism of urokinase-type plasminogen activator is interacting with plasminogen activator inhibitor-1 to raise risk of cervical neoplasia.PMID 22354580Read ↗

Genetic polymorphism of the plasminogen activator inhibitor-1 is associated with an increased risk of endometrial cancer.Semantic proximity Read ↗

Evaluation of the association of urokinase plasminogen activator system gene polymorphisms with susceptibility and pathological development of hepatocellular carcinoma.Semantic proximity Read ↗

Impact of uPA system gene polymorphisms on the susceptibility of environmental factors to carcinogenesis and the development of clinicopathology of oral cancer.Semantic proximity Read ↗

The Urokinase Plasminogen Activator System in Human Cancers: An Overview of Its Prognostic and Predictive RoleSemantic proximity Read ↗

The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer.Semantic proximity Read ↗

Diversity and functional evolution of the plasminogen activator system.Semantic proximity Read ↗

Good or bad: Paradox of plasminogen activator inhibitor 1 (PAI-1) in digestive system tumorsSemantic proximity Read ↗

PAI-1 Polymorphisms Have Significant Associations With Cancer Risk, Especially Feminine Cancer.Semantic proximity Read ↗

RIPK1 Polymorphisms Alter the Susceptibility to Cervical Cancer among the Uyghur population in ChinaSemantic proximity Read ↗

RIPK1 polymorphisms alter the susceptibility to cervical Cancer among the Uyghur population in China.Semantic proximity Read ↗

What is the impact of plasminogen activator inhibitor type 1 (PAI-1) gene polymorphism on gynecological malignancies: a retrospective studySemantic proximity Read ↗

Association of a genetic variant in the angiopoietin-like protein 4 gene with cervical cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.